PT  - JOURNAL ARTICLE
AU  - Alhemyadi, Salwa A.
AU  - Elawad, Mamoun
AU  - Fourtounas, Konstantinos
AU  - Abdrabbou, Zakaria
AU  - Alaraki, Bellalah
AU  - Younis, Siddeg
AU  - Nawaz, Zahir
AU  - Alqurashi, Salem
AU  - Mohamed, Sarar
TI  - Screening for Fabry disease among 619 hemodialysis patients in Saudi Arabia
AID  - 10.15537/smj.2020.8.25184
DP  - 2020 Aug 01
TA  - Saudi Medical Journal
PG  - 813--818
VI  - 41
IP  - 8
4099  - http://smj.org.sa/content/41/8/813.short
4100  - http://smj.org.sa/content/41/8/813.full
SO  - Saudi Med J2020 Aug 01; 41
AB  - Objectives: To determine the prevalence of Fabry disease (FD) among Saudi patients on hemodialysis.Methods: This prospective study was conducted in 3 major hospitals in the. All adult patients (>18 years old) attending the dialysis unit who have end-stage renal disease (ESRD) and on hemodialysis were included. Known patients with FD and those who refused to participate in the study were excluded. All eligible patients were screened for FD using dry blood spot (DBS) for alpha-galactosidase A (α-Gal A). A positive DBS (enzyme activity <40%) was followed by another confirmatory enzyme assay. When the second DBS sample was also positive (enzyme activity <40%), a Sanger sequencing of the GLA gene was performed.Results: A total of 619 patients with ESRD and on hemodialysis were screened for FD using DBS for α-Gal A enzyme level. Enzymatic activity was below 40% in 11 samples. On retesting, 3 females had <20% enzymatic activity suggesting FD. Sanger sequencing of these 3 females showed the variant c.1055C>G (p.Ala352Gly) confirming the diagnosis of FD. Family screening of one of these 3 patients revealed one asymptomatic female carrying the same variant.Conclusion: The prevalence of FD in this cohort was 4.8 per 1000 patients. Screening of Fabry patients with ESRD seems to be a cost-effective strategy. Furthermore, relatives of the patients identified by screening enhances this screening strategy.